Advertisement
U.S. markets closed
  • S&P Futures

    5,204.50
    -10.25 (-0.20%)
     
  • Dow Futures

    39,188.00
    -35.00 (-0.09%)
     
  • Nasdaq Futures

    18,163.75
    -67.75 (-0.37%)
     
  • Russell 2000 Futures

    2,045.70
    -4.10 (-0.20%)
     
  • Crude Oil

    82.56
    -0.16 (-0.19%)
     
  • Gold

    2,162.90
    -1.40 (-0.06%)
     
  • Silver

    25.26
    0.00 (0.00%)
     
  • EUR/USD

    1.0872
    -0.0005 (-0.04%)
     
  • 10-Yr Bond

    4.3400
    +0.0360 (+0.84%)
     
  • Vix

    14.33
    -0.08 (-0.56%)
     
  • GBP/USD

    1.2720
    -0.0009 (-0.07%)
     
  • USD/JPY

    149.2910
    +0.1930 (+0.13%)
     
  • Bitcoin USD

    65,906.53
    -1,723.70 (-2.55%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,722.55
    -4.87 (-0.06%)
     
  • Nikkei 225

    39,454.64
    -285.80 (-0.72%)
     

CTI BioPharma's Pacritinib Demonstrates Positive Safety Profile In Graft-Versus-Host-Disease Study

CTI BioPharma Corp (NASDAQ: CTIC) has announced that Clinical Cancer Research, a journal of the American Association for Cancer Research, has published results from a Phase 1 study evaluating pacritinib, to prevent acute graft-versus-host disease (GVHD).

  • Pacritinib showed an encouraging safety profile and exhibited preliminary therapeutic activity in preventing acute GVHD after allogeneic hematopoietic cell transplantation.

  • The Phase 2 portion of the trial is designed to evaluate the therapeutic effect of pacritinib in combination with sirolimus and low-dose tacrolimus for GVHD prevention.

  • The Phase 1 portion of the trial evaluated the safety of pacritinib when administered with sirolimus, plus low-dose tacrolimus after allogeneic hematopoietic cell transplantation.

  • A 3+3 dose escalation design identified Pacritinib 100 mg twice a day as the minimum biologically active and well-tolerated dose for further study.

  • The new manuscript reports that dual JAK2/mTOR inhibition suppresses pathogenic Th1 and Th17 cells, enhances the potency of immunosuppressive regulatory T cells (Tregs) and maintains natural killer cells and CD8+ cytotoxic T lymphocytes required for graft-versus-leukemia.

  • Notably, PAC/SIR/TAC was observed to preserve donor cytomegalovirus (CMV) immunity, permit timely engraftment, and avoid cytopenias observed with nonselective JAK inhibitors.

  • Pacritinib is an oral kinase inhibitor with specificity for JAK2, IRAK1, and CSF1R. The JAK family of enzymes is a central component in signal transduction pathways, which are critical to normal blood cell growth and development and inflammatory cytokine expression and immune responses.

  • Price Action: CTIC shares trading 2.03% higher at $3.27 in market hours on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement